[Maternal blood and amniotic fluid insulin-like growth factor detection and amniotic cavity drug delivery for early diagnosis and management of fetal growth restriction].

OBJECTIVE: To explore the relationship between insulin-like growth factors (IGFs) and fetal growth restriction (FGR) and early treatment of FGR. METHODS: The levels of IGF-I and IGF-II were detected with radioimmunoassay in maternal blood and amniotic fluid samples of 44 pregnant women with FGR and 36 normal gravidas. The 44 gravidas with FGR were randomized into treatment group with amino acid by a pediatric administration to the amniotic cavity formula and control group with intravenous infusion of compound amino acid. The therapeutic effects were compared between the two groups on the basis of B-type ultrasound findings. RESULTS: Maternal blood IGF-I and amniotic fluid IGF-I and IGF-II levels in the pregnant women with FGR were significantly lower than those in normal gravidas (P<0.01). After therapy, IGF-I and IGF-II levels were significantly increased in the treatment group (P<0.01), but no obvious changes in IGF-I and IGF-II levels were observed in the control group (P>0.05). Compared with the control group, IGF-I and IGF-II levels increased significantly in the amniotic fluid in the treatment group, with also marked elevation of IGF-I levels in maternal blood (P<0.01). Better therapeutic effects were achieved in the treatment group than in the control group (P<0.01), and the birth weights of the neonates in the treatment group were basically normal. CONCLUSIONS: Detection of amniotic fluid IGF-I and IGF-II and maternal blood IGF-I can help predict the condition and facilitate early diagnosis of FGR. Injection of pediatric amino acid into the amniotic cavity can be effective for treatment of FGR.

[Study about seroconversion of HBV NAT screening-positive crowd from blood donors].

OBJECTIVE: To investigate the characteristics of seroconversion of HBV NAT screening-positive crowd from blood donors in Dongguan city and provide reference for the safety of blood transfusion and disease prevention. METHODS: With retrospective survey, Nucleic acid testing (NAT) was used to analyze 28800 HBsAg-negative samples by ELISA from blood donors in Dongguan city from August, 2006 to August, 2007 with Roche Cobas AmpliScreen systems; and follow-up research including NAT for HBV-DNA, ELISA for HBsAg and multiple factors analysis for HBV infection was carried out on HBV NAT screening-positive crowd. RESULTS: 10 positive pooling were screened from 28800 samples; after further detection, 2 of these positive pooling were HBV-DNA negative and 8 HBV-DNA positive samples were found.The 10-week follow-up research on these 8 blood donors showed that 6 were HBV-DNA positive and HBsAg-negative at 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks respectively, 1 was not HBsAg positive until 2 weeks and was positive on follow-up, and considered in "window period", 1 was HBV-DNA negative, HBsAg-negative on follow-up. Of these 8,7 were not only migrant laborers with poor condition of work, life and health but also in high risk of secondary infection for HBV, in addition they had little idea of therapy or prevention measures of HBV infection and the other 1 was HBV-DNA negative, HBsAg-negative on follow-up, who was in better condition than the above 7 donors. CONCLUSION: NAT is more sensitive than ELISA in screening HBV, but the probability of being false positive of NAT can not be ignored at the same time. On the hand, only screening HBsAg for HBV is relative limitation in high infection region of China. Some factors would have effect on the serum conversion of blood donors including the quality of work and life, therapy or prevention measures.